Literature DB >> 9886810

The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.

T Deak1, K T Nguyen, A L Ehrlich, L R Watkins, R L Spencer, S F Maier, J Licinio, M L Wong, G P Chrousos, E Webster, P W Gold.   

Abstract

The nonpeptide CRH antagonist antalarmin has been shown to block both behavioral and endocrine responses to CRH. However, it's potential activity in blunting behavioral and endocrine sequelae of stressor exposure has not been assessed. Because antagonism of central CRH by alpha-helical CRH attenuates conditioned fear responses, we sought to test antalarmin in this regard. In addition, it remains unclear as to whether this is a result of receptor blockade during conditioning or during testing. Thus, we explored whether CRH mediates the induction or expression of conditioned fear (freezing in a context previously associated with 2 footshocks; 1.0 mA, 5 sec each). Furthermore, because rats previously exposed to inescapable shock (IS; 100 shocks, 1.6 mA, 5 sec each), demonstrate enhanced fear conditioning, we investigated whether this effect would be blocked by antalarmin. Antalarmin (20 mg/kg x 2 ml i.p.) impaired both the induction and expression of conditioned fear. In addition, antalarmin blocked the enhancement of fear conditioning produced by prior exposure to IS. Despite the marked behavioral effects observed in antalarmin-treated rats, antalarmin had no effect on IS-induced rises in ACTH or corticosterone. However, antalarmin did block the ACTH response produced by exposure to 2 footshocks.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886810     DOI: 10.1210/endo.140.1.6415

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  63 in total

1.  Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.

Authors:  K E Habib; K P Weld; K C Rice; J Pushkas; M Champoux; S Listwak; E L Webster; A J Atkinson; J Schulkin; C Contoreggi; G P Chrousos; S M McCann; S J Suomi; J D Higley; P W Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  CRF₂ mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats.

Authors:  Javier Navarro-Zaragoza; Cristina Núñez; Jessica Ruiz-Medina; M Luisa Laorden; Olga Valverde; M Victoria Milanés
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Treatment with a CRH-R1 antagonist prevents stress-induced suppression of the central neural drive to the reproductive axis in female macaques.

Authors:  S M Herod; C R Pohl; J L Cameron
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-09-07       Impact factor: 4.310

4.  Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.

Authors:  Tanja Jovanovic; Erica J Duncan; Joanna Kaye; Kristie Garza; Seth D Norrholm; Sabra S Inslicht; Thomas C Neylan; Sanjay J Mathew; Dan Iosifescu; Barbara O Rothbaum; Helen S Mayberg; Boadie W Dunlop
Journal:  Psychophysiology       Date:  2019-02-26       Impact factor: 4.016

5.  Sex differences in corticotropin-releasing factor receptor-1 action within the dorsal raphe nucleus in stress responsivity.

Authors:  Alexis R Howerton; Alison V Roland; Jessica M Fluharty; Anikò Marshall; Alon Chen; Derek Daniels; Sheryl G Beck; Tracy L Bale
Journal:  Biol Psychiatry       Date:  2013-10-23       Impact factor: 13.382

6.  A sexually dimorphic distribution of corticotropin-releasing factor receptor 1 in the paraventricular hypothalamus.

Authors:  Zachary J Rosinger; Jason S Jacobskind; Rose M De Guzman; Nicholas J Justice; Damian G Zuloaga
Journal:  Neuroscience       Date:  2019-05-02       Impact factor: 3.590

7.  Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear.

Authors:  D T Hubbard; B R Nakashima; I Lee; L K Takahashi
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

8.  Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking.

Authors:  Andrea Cippitelli; Ruslan Damadzic; Anita C Hansson; Erick Singley; Wolfgang H Sommer; Robert Eskay; Annika Thorsell; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

Review 9.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress.

Authors:  Sayamwong E Hammack; Megan J Schmid; Matthew L LoPresti; Andre Der-Avakian; Mary Ann Pellymounter; Alan C Foster; Linda R Watkins; Steven F Maier
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.